BOCA RATON, Fla., April 27, 2017 /PRNewswire/ -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device companyspecializing in the non-invasive treatment of non-melanoma skin cancers and keloids, with superficial radiation therapy (SRT), announced today that management will hold a conference call beginning at 4:30 p.m. Eastern Time
To access the conference call, the dial-in numbers are 1-877-870-4263 (U.S. Toll Free), 1-412-317-0790 (International) and 1-855-669-9657 (Canada Toll Free). Please ask the operator to be connected to the Sensus Healthcare call.
Following the conclusion of the conference call, a replay will be available through May 11, 2017 and can be accessed by dialing 1-877-344-7529 (U.S. Toll Free), 1-412-317-0088 (International), and 1-855-669-9658 (Canada Toll Free). All listeners should provide the replay passcode 10106354. The call will also be archived on the Company website for a time at http://www.sensushealthcare.com
About Sensus Healthcare
Sensus Healthcare, Inc. is a medical device company that is committed to enabling non-invasive and cost-effective treatment of non-melanoma skin cancers and keloids. Sensus uses a proprietary low energy X-ray radiation technology known as superficial radiation therapy (SRT), which is a result of over a decade of dedicated research and development activities. Sensus has successfully incorporated the SRT therapy into its portfolio of treatment devices, the SRT-100™ and SRT-100 Vision™. To date, the SRT technology has been used to effectively and safely treat oncological and non-oncological skin conditions in thousands of patients. For further information, please visit http://www.sensushealthcare.com
Investors LHAKim Sutton Golodetz(212) email@example.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/sensus-healthcare-to-host-first-quarter-2017-financial-results-and-business-update-conference-call-on-may-4-2017-300446772.html
SOURCE Sensus Healthcare
Subscribe to our Free Newsletters!
Angiogenesis is the process of formation of new blood vessels from pre-existing blood vessels. It ...
Aniridia is a genetic eye disorder in which the iris is partially or entirely absent. It is ...
Cachexia refers to severe muscle and fat loss, anorexia and marked weight loss due to an underlying ...View All